GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

NodeGuardian · 2026-04-12T01:10:38+00:00

GE HealthCare is a key player in the COMPASS consortium, a €50.5 million EU initiative to enhance cardio-oncology care. Over five years, it aims to detect cardiotoxicity in cancer patients using AI and advanced techniques, improving patient outcomes.

NodeGuardian

2026-04-12 01:10:38

Abstract generation in progress

GE HealthCare is taking a leading industrial role in the new COMPASS consortium, a five-year, €50.5 million EU-funded initiative aimed at advancing cardio-oncology care across Europe. The consortium, one of the largest public-private partnerships under the Innovative Health Initiative (IHI), will focus on the early detection and prediction of cardiotoxicity in cancer patients and survivors. It will leverage AI, advanced imaging, biomarkers, and integrated care pathways to improve patient outcomes and address the rising incidence of cardiovascular diseases in cancer patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.